

Krebs Biochemicals & Industries Limited

8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034

CIN : L24110TG1991PLCO13511



12th February, 2016

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001

Dear Sir/Madam,

Sub: Submission of Unaudited Financial Results for the quarter ended 31st December, 2015

Ref: Reg.33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to the above captioned subject, we herewith submit you the unaudited financial results and the Limited Review Report of the Statutory Auditors for the quarter and 9 months ended 31st December, 2015, which was taken on record at the Board Meeting held on 12th February, 2016.

Kindly take the same into your records.

Thanking You,

Yours Faithfully,

For Krebs Biochemicals & Industries Limited


Haritha Varanasi *
Company Secretary



KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN: L24110TG1991PLC013511

Regd. Office: Plot No:38, 8-2-577/B, Maas Heights, Road No:2, Banjara Hills, Hyderabad -500034

STAND ALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2015

(Rs. In lacs)

	Particulars	Quarter Ended			Nine Months Ended		Previous Year Ended (6 Months)
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
	PART - 1						
1	Income from Operations						
	a) Net Sales / Income from Operations (Net of Excise Duty)	-	-	-	15.85	-	-
	b) Other Operating Income	40.27	34.21	-	74.48	-	-
	Total Income from operations (net)	40.27	34.21	-	90.33	-	-
2	Expenses						
	a. Cost of Material Consumed	(8.48)	166.84	-	175.64	-	(23.11)
	b. Changes in inventories of finished goods, work-in-progress and stock -in-trade	18.85	(241.64)	-	(227.98)	-	23.11
	c. Employee benefits expense	120.83	109.08	67.94	368.44	(227.38)	185.67
	d. Depreciation and Amortisation expense	95.54	95.54	-	286.62	-	187.13
	e. Other Manufacturing Expenses	82.70	160.32	24.83	356.66	24.88	90.76
	f. Other Expenses	60.07	99.57	47.03	222.54	134.70	213.82
	Total Expenses	369.51	389.71	139.80	1,181.92	(67.80)	677.38
3	Profit / (Loss) from Operations before other income, finance costs and exceptional items (1 - 2)	(329.24)	(355.50)	(139.80)	(1,091.59)	67.80	(677.38)
4	Other Income	2.38	60.76	-	63.89	1.81	1.12
5	Profit / (Loss) from ordinary activities before finance costs & exceptional items (3 ± 4)	(326.86)	(294.74)	(139.80)	(1,027.70)	69.61	(676.26)
6	Finance Costs	20.90	4.07	0.25	25.17	1.04	402.85
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 ± 6)	(347.76)	(298.81)	(140.05)	(1,052.87)	68.57	(1,079.11)
8	Exceptional Items:						
	a) Debit balances written off	-	-	-	-	-	(692.16)
	b) Waiver of Principal of Bank Loans & Others	-	-	-	-	-	3,625.17
	c) Depletion in Value of Inventory	-	(126.93)	-	(126.93)	-	(2,637.91)
	d) Amounts Written Back	19.56	18.07	-	89.66	-	-
	e) Profit on Sale of Food Division's Immovable Assets	-	-	-	59.12	-	-
	f) Excess Provision of Earlier Period Written Back	-	-	-	-	15.55	-
9	Profit / (Loss) from Ordinary activities before tax (7 ± 8)	(328.20)	(407.67)	(140.05)	(1,031.02)	84.12	(784.01)
10	Tax Expense	-	-	-	-	(39.99)	-
11	Net Profit / (Loss) from ordinary activities after Tax (9 ± 10)	(328.20)	(407.67)	(140.05)	(1,031.02)	44.13	(784.01)
12	Extra Ordinary Items	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12)	(328.20)	(407.67)	(140.05)	(1,031.02)	44.13	(784.01)
14	Share of Profit / (Loss) of Associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / (Loss) after Taxes, minority Interest & Share of Profit/ (Loss) of Associates (13 ± 14 ± 15)	(328.20)	(407.67)	(140.05)	(1,031.02)	44.13	(784.01)
17	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	1306.43	1241.43	951.43	1306.43	951.43	951.43
18	Reserve Excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year	NA	NA	NA	NA	NA	(1,407.92)
19 (i)	Earning Per Share (before extraordinary Items) (of Rs.10/- each) (not Annualised)						
	(a) Basic	(2.51)	(3.28)	(1.47)	(7.89)	0.46	(8.24)
	(b) Diluted	(2.51)	(3.28)	(1.47)	(7.89)	0.46	(8.24)
19 (ii)	Earning Per Share (after extraordinary Items) (of Rs.10/- each) (not Annualised)						
	(a) Basic	(2.51)	(3.28)	(1.47)	(7.89)	0.46	(8.24)
	(b) Diluted	(2.51)	(3.28)	(1.47)	(7.89)	0.46	(8.24)

1 The above results have been reviewed by the Audit Committee at its meeting held on 12th February, 2016 and approved by the Board of Directors of the Company at its meeting held on 12th February, 2016.

2 The Above results are subjected to limited review by Company's Statutory Auditors.

3 The Company is operating in one segment only hence no segment results have been disclosed.

4 Figures have been regrouped, rearranged wherever necessary.


5 The company has allotted 6.50 lacs equity shares and 6.80 lacs convertible warrants on 03.10.2015 and the same was approved by share holders on 11.03.2015

Place : Hyderabad

Date : 12.02.2016

Avinash Ray

Managing Director





PAVULURI & Co.

CHARTERED ACCOUNTANTS

105, 1st Block, 1st Floor, Divya Shakti Complex,
Ameerpet, Hyderabad - 500 016.

Ph : 040 - 2373 1837, 4025 8691

Fax : 040 - 2374 8729

Email : pavuluriandco@gmail.com

pavuluriandco@hotmail.com

Review Report to the Board of Directors of Krebs Bio-chemicals & Industries Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Krebs Bio-chemicals & Industries Limited** (" the company") for the quarter **31st December, 2015** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results for the Quarter ended 31st December 2015 prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date : 12.02.2016

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S


(CA. N. RAJESH)
PARTNER
M.No: F-223169

